Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Moderna Shares Rally After Topping Q2 Estimates

Stock Markets Aug 03, 2022 10:15AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters Moderna (MRNA) Shares Rally After Topping Q2 Estimates

By Sam Boughedda

Moderna (NASDAQ:MRNA) shares jumped more than 13% in early Wednesday trading after it posted earnings before the open Wednesday, topping analyst earnings and revenue consensus estimates.

The pharmaceutical company revealed second-quarter earnings of $5.24 per share, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.

Moderna's said its revenue increase was primarily due to $4.5 billion in product sales, driven by increased sales of the company's COVID-19 vaccine.

However, its cost of sales was $1.4 billion, or 30% of product sales, including a charge of $499 million for inventory write-downs related to its Covid vaccine, while there was also a loss on firm purchase commitments of $184 million. Moderna put the loss down to a "substantial reduction" of its expected deliveries to COVAX and a deferral of deliveries to other customers, particularly to the European Union.

Moderna reiterated advance purchase agreements for expected delivery in 2022 of approximately $21 billion. In addition, it announced a new $3 billion share repurchase plan.

"Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet with $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing. We will continue to invest and grow as we have never been as optimistic about Moderna's future. Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology," said Stephane Bancel, Chief Executive Officer of Moderna.

Moderna Shares Rally After Topping Q2 Estimates
 

Related Articles

Micron tempers fourth-quarter revenue forecast
Micron tempers fourth-quarter revenue forecast By Reuters - Aug 09, 2022

(Reuters) - Memory chipmaker Micron Technology (NASDAQ:MU) said on Tuesday that its fourth-quarter revenue may come in at or below the low end of the forecast range provided on...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email